TNFRSF8 and Hodgkins lymphoma: Although the CD30 overexpression is a common hallmark of HL and BV/MMAE has demonstrated clinical efficacy in the treatment of naive and relapsed patients, a small subset of triple refractory patients with cHL is emerging; therefore, it is of crucial importance to introduce potential pharmacological combinations to enhance therapy effectiveness.